Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.

Naim Alkhouri, MD, on when to judge MASH treatment response, counseling on weight and muscle loss, primary care screening, and future trial end points.

People with multiple sclerosis make up most of a survey linking variable-friction footwear to fewer self-reported falls.

Clinicians at an AJMC roundtable in Cleveland said Medicare's GLP-1 Bridge came late and that cost and capacity gaps persist.

Nathan Estrada, DPT, explains which patients, including those with multiple sclerosis, may benefit from footwear that adapts to gait.

The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).

AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.

October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.